文献速递核素与放射性配体治疗肿瘤 PET/CT

多西他赛治疗后177Lu-PSMA-617巩固治疗在同步高瘤负荷转移性激素敏感性前列腺癌患者中的随机2期试验

177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial.
PubMed 文献 · J Nucl Med · 2025-07-01

CONSOLIDATE试验将30例同步高瘤负荷mHSPC患者按1:1随机分为177Lu-PSMA-617巩固治疗组(7.4 GBq/周期×2,间隔6周)和对照组(仅标准化疗)。实验组6个月PSA≤0.2 ng/mL比例为60% vs 对照组13%(RR 4.5,P=0.008),客观影像学缓解率53% vs 7%,未见3/4级毒性,但试验因入组缓慢提前终止,作者认为需更大规模3期试验确认生存获益。

要点

  • 同步高瘤负荷mHSPC化疗后残留病变,177Lu-PSMA-617巩固治疗6个月PSA≤0.2 ng/mL达60%,对照组13%。
  • 客观影像学缓解率实验组53% vs 对照组7%,差异有统计学意义(P=0.014)。
  • 实验组未观察到3级或4级毒性,但试验因入组缓慢提前终止,需3期试验确认生存获益。

核心结论

  • 在同步高瘤负荷mHSPC患者化疗后残留病变中,177Lu-PSMA-617巩固治疗显示出有希望的疗效和安全性。
  • 作者认为需要更大规模的3期试验来明确确立其生存获益。

研究设计与样本

  • 由研究者发起的随机、平行组、开放标签2期试验(CONSOLIDATE)。
  • 纳入同步高瘤负荷mHSPC患者,接受雄激素剥夺治疗联合多西他赛,多西他赛完成后存在残留非进展性疾病(定义为PSA>0.2 ng/mL且68Ga-PSMA-11 PET/CT显示PSMA阳性病变)。
  • 按1:1随机分为实验组(177Lu-PSMA-617,7.4 GBq/周期×2,间隔6周,允许方案规定的标准治疗)或对照组(仅方案规定的标准治疗)。
  • 试验因冠状病毒病疫情后入组缓慢及mHSPC治疗指南变化而提前终止,2021年1月至2024年6月共随机30例高瘤负荷mHSPC患者。

主要发现

  • 主要终点:随机后6个月PSA≤0.2 ng/mL比例实验组为15例中9例(60%;95%CI 35%-85%),对照组为15例中2例(13%;95%CI 0%-30%)(风险比4.5;95%CI 1.2-17.4;P=0.008)。
  • 客观影像学缓解率实验组为15例中8例(53%;95%CI 28%-78%),对照组为15例中1例(7%;95%CI 0%-19%)(P=0.014)。
  • 估计中位影像学无进展生存期实验组18个月(95%CI 9-27个月)vs 对照组9个月(95%CI 4-14个月)。
  • 估计中位PSA无进展生存期实验组15个月(95%CI 12-18个月)vs 对照组9个月(95%CI 1-17个月)。
  • 实验组加用177Lu-PSMA-617未观察到3级或4级毒性。

关键数值与推荐

  • 主要终点:随机后6个月PSA≤0.2 ng/mL比例实验组60% vs 对照组13%(风险比4.5;95%CI 1.2-17.4;P=0.008)。
  • 客观影像学缓解率实验组53% vs 对照组7%(P=0.014)。
  • 估计中位影像学无进展生存期实验组18个月 vs 对照组9个月。
  • 估计中位PSA无进展生存期实验组15个月 vs 对照组9个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验因冠状病毒病疫情后入组缓慢及mHSPC治疗指南变化而提前终止。
  • 作者认为需要更大规模的3期试验来明确确立其生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) has shown positive survival outcomes in metastatic castration-resistant prostate cancer. However, there are limited data in the hormone-sensitive setting. Here, in the CONSOLIDATE trial (177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer), we intended to evaluate the role of 177Lu-PSMA-617 as consolidation therapy for residual disease after chemohormonal treatment in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer (mHSPC). Methods: This was an investigator-initiated randomized, parallel-group, open-label phase 2 trial. Synchronous high-volume mHSPC patients treated with androgen-deprivation therapy plus docetaxel and having residual nonprogressive disease after docetaxel completion (defined as prostate-specific antigen [PSA] > 0.2 ng/mL with PSMA-positive disease on 68Ga-PSMA-11 PET/CT) were randomized in a 1:1 ratio to the experimental arm (177Lu-PSMA-617, 7.4 GBq/cycle × 2, 6 wk apart with protocol-permitted standard of care) or control arm (protocol-permitted standard of care alone). The primary endpoint was the proportion of patients achieving a PSA level of 0.2 ng/mL or less at 6 mo from randomization. Secondary endpoints included objective radiographic response rate, radiographic progression-free survival (PFS), PSA PFS, and toxicities. Results: The trial was terminated early because of poor accrual after the coronavirus disease pandemic and a change in treatment guidelines for mHSPC. Thirty high-volume mHSPC patients were randomized between January 2021 and June 2024. The primary endpoint was achieved in 9 of 15 (60%; 95% CI, 35%-85%) patients in the experimental arm versus 2 of 15 (13%; 95% CI, 0%-30%) in the control arm (risk ratio, 4.5; 95% CI, 1.2-17.4; P = 0.008). The objective radiographic response rates were 8 of 15 (53%; 95% CI, 28%-78%) and 1 of 15 (7%; 95% CI, 0%-19%) in the experimental and control arms, respectively (P = 0.014). The estimated median radiographic PFS and PSA PFS were 18 mo (95% CI, 9-27 mo) and 15 mo (95% CI, 12-18 mo), respectively, in the experimental arm versus 9 mo (95% CI, 4-14 mo) and 9 mo (95% CI, 1-17 mo), respectively, in the control arm. No grade 3 or 4 toxicity was noted with the addition of 177Lu-PSMA-617 in the experimental arm. Conclusion: In synchronous high-volume mHSPC patients having residual disease after chemohormonal treatment, 177Lu-PSMA-617 consolidation therapy demonstrated promising efficacy and safety outcomes. Larger phase 3 trials are warranted to definitively establish its survival benefit.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Das CK, Goyal S, et al. 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial. J Nucl Med. 2025. PMID: 40404393. doi:10.2967/jnumed.125.269913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。